Nicholas J. Vogelzang, MD, FASCO, FACP, explains the influence of CHAARTED and STAMPEDE

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancerПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the influence of an AR-V7 commercial testПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, regarding sipuleucel-T in mCRPCПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, regarding the evolution of ADT in prostate cancerПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, describes the role of PARP inhibitors advanced prostate cancerПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patientsПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancerПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, considers data from CHAARTED, STAMPEDE, and LATTITUDEПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugsПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, on the evolving treatment landscape of nmCRPCПодробнее

Nicholas J. Vogelzang, MD, on how we can avoid under-diagnosing & over-diagnosing prostate cancerПодробнее

Nicholas Vogelzang, MD, FASCO, FACP | Perspective on Cancer Care in the Time of COVID-19Подробнее

Nicholas Vogelzang, MD, FASCO, FACP, regarding combination pembrolizumab and olaparib in mCRPCПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, on identifying the best patients for Zytiga versus XtandiПодробнее

Nicholas Vogelzang, MD, FASCO, FACP | Addressing Patients on Cancer Care in the Time of COVID-19Подробнее

Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancerПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelinesПодробнее

Nicholas Vogelzang, MD, explains how cabazitaxel should be used in various lines of treatment in mPCПодробнее

Nicholas Vogelzang, MD, FASCO, FACP, provides updates on PSMA radioligands for PET imagingПодробнее